HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis

This item is licensed under: Creative Commons Attribution 4.0 International

Files in This Item:
journal.pone.0209615.pdf1.48 MBPDFView/Open
Please use this identifier to cite or link to this item:

Title: Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis
Authors: Kawagishi, Naoki Browse this author
Suda, Goki Browse this author →KAKEN DB
Nakamura, Akinobu Browse this author →KAKEN DB
Kimura, Megumi Browse this author
Maehara, Osamu Browse this author
Suzuki, Kazuharu Browse this author
Nakamura, Akihisa Browse this author
Ohara, Masatsugu Browse this author
Izumi, Takaaki Browse this author
Umemura, Machiko Browse this author
Nakai, Masato Browse this author
Sho, Takuya Browse this author
Natsuizaka, Mitsuteru Browse this author →KAKEN DB
Morikawa, Kenichi Browse this author
Ogawa, Koji Browse this author →KAKEN DB
Kudo, Yusuke Browse this author
Nishida, Mutsumi Browse this author →KAKEN DB
Miyoshi, Hideaki Browse this author →KAKEN DB
Sakamoto, Naoya Browse this author →KAKEN DB
Issue Date: 2018
Publisher: The Public Library of Science (PLOS)
Journal Title: PLOS ONE
Volume: 13
Issue: 12
Start Page: e0209615
Publisher DOI: 10.1371/journal.pone.0209615
Abstract: Aim: We comprehensively analyzed how hepatitis C virus (HCV) eradication by interferon (IFN)-free direct-acting-antiviral-agents (DAAs) affects liver steatosis and atherogenic risk. Methods: Patients treated with IFN-free-DAAs who underwent transient elastography before and at 24-weeks post-treatment, including controlled attenuation parameter (CAP), and achieved sustained viral response (SVR) were enrolled. The association between changes in liver steatosis, lipid-metabolism, and genetic and clinical factors was analyzed. Results: A total of 117 patients were included. The mean CAP and low-density lipoprotein cholesterol (LDL-C) levels were significantly elevated at SVR24. However, baseline LDL-C and CAP values were significantly negatively correlated with changes in these values after HCV eradication, indicating that in patients with high baseline values, the values generally decreased after HCV eradication. Mean small-dense LDL-C (sdLDL-C), which has greater atherogenic potential, was significantly elevated only in patients with both dyslipidemia (LDL-C >140 mg/dL) and liver steatosis (CAP >248 dB/m) at SVR24. Those patients had significant higher baseline BMI, LDL-C, and total-cholesterol levels. Conclusions: Generally, successful HCV eradication by IFN-free-DAAs decreases CAP and LDL-C in patients with high baseline values. However, elevated LDL-C was accompanied with elevated sdLDL-C only in patients with liver steatosis and dyslipidemia at SVR24; therefore, those patients may require closer monitoring.
Type: article
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 三好 秀明

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 - Hokkaido University